Loading...
•
Jun 30, 2023
Voyager Therapeutics Q2 2023 Earnings Report
Voyager Therapeutics reported financial results for the second quarter of 2023, highlighted by collaboration revenue increase and a net loss.
Key Takeaways
Voyager Therapeutics reported a net loss of $22.2 million for Q2 2023, compared to a net loss of $19.1 million for the same period in 2022. Collaboration revenue increased to $4.9 million from $0.7 million year-over-year, driven by collaborations with Neurocrine Biosciences. The company's cash, cash equivalents, and marketable securities totaled $272.7 million as of June 30, 2023.
Launched new vectorized anti-Aβ antibody early research initiative for Alzheimer’s disease.
Entered into a licensing agreement with Sangamo for a potential prion disease treatment.
Presented data at ASGCT 2023, demonstrating increased brain transduction of IV-administered TRACER™ capsids.
Anti-tau antibody program VY-TAU01 remains on track for IND in the first half of 2024.
Revenue by Segment
Forward Guidance
Voyager expects its cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...